ストックスクリーナーアプリを入手
21.93
1.31%
-0.29
プレマーケット:
21.93
Denali Therapeutics Inc (DNLI) 最新ニュース
(DNLI) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Denali Therapeutics (DNLI) Rallies Over 3% as Stock Tests Key Resistance LevelsStock Analysis - newsline.com
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names - Insider Monkey
10 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
LRRK2 inhibitor failure pushes Parkinson’s field toward genetic enrichment - BioCentury
Denali Therapeutics stock (US24823R1077): Alzheimer’s data and Roche deal keep Wall Street watchin - AD HOC NEWS
Denali stock dips as Biogen-partnered Parkinson's disease study fails - MSN
Denali Therapeutics (DNLI) grants RSUs and stock options to director - Stock Titan
Denali Therapeutics (DNLI) director granted RSUs and options in new award - Stock Titan
Denali Therapeutics (DNLI) director receives RSU and stock option awards - Stock Titan
Director at Denali Therapeutics (NASDAQ: DNLI) receives RSUs and options - Stock Titan
Denali Therapeutics (DNLI) director receives new RSU and stock option grants - Stock Titan
Denali Therapeutics (DNLI) director granted RSUs and stock options in new equity awards - Stock Titan
Denali Therapeutics (NASDAQ: DNLI) details Baker RSU and stock option grants - Stock Titan
Denali Therapeutics (DNLI) 2026 meeting backs board slate, auditor and executive pay - Stock Titan
Responsive Playbooks and the DNLI Inflection - Stock Traders Daily
DNLI PE Ratio & Valuation, Is DNLI Overvalued - Intellectia AI
DNLI.O Technical Analysis & Stock Price Forecast - Intellectia AI
Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos - Insider Monkey
Does Denali Therapeutics (DNLI) Parkinson’s Setback Reveal a Deeper Shift in Its Neuroscience Strategy? - simplywall.st
DNLI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
DNLI Q1 loss narrower than expected, Avlayah approval boosts prospects - MSN
A Look At Denali Therapeutics (DNLI) Valuation After Phase 2b Trial Failure Refocuses Attention On Its Pipeline - Sahm
Biogen and Denali halt BIIB122 trial for idiopathic Parkinson’s - Parkinson's News Today
DNLI gains 25.4% year to date: Should you buy, sell or hold the stock? - MSN
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval - AOL.com
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data - Seeking Alpha
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says - Moomoo
DNLI Maintained by Morgan Stanley -- Price Target Lowered to $35 - GuruFocus
Biogen and Denali discontinue Parkinson’s candidate BIIB122 after Phase IIb LUMA study miss - Manufacturing Chemist
Biogen, Denali to drop Parkinson’s therapy after mid-stage trial setback - MSN
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42 - Moomoo
Understanding the Setup: (DNLI) and Scalable Risk - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: Denali Therapeutics (DNLI), Intuitive Surgical (ISRG) - The Globe and Mail
Biogen (BIIB) and Denali (DNLI) Halt Development of BIIB122 Afte - GuruFocus
Is Early AVLAYAH Demand Reshaping The Investment Case For Denali Therapeutics’ Rare-Disease Platform (DNLI)? - Sahm
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks - Yahoo Finance UK
Biogen and Denali Halt Development of BIIB122 After Phase 2b LUMA Study Fails in Early Parkinson’s Disease - Minichart
Morgan Stanley Cuts Price Target on Denali Therapeutics to $35 From $40, Keeps Overweight Rating - Moomoo
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails - Yahoo Finance
Deutsche Bank Adjusts Denali Therapeutics Price Target to $31 From $35, Maintains Buy Rating - Moomoo
Denali Therapeutics stock falls after Parkinson’s drug fails trial By Investing.com - Investing.com South Africa
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):